Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
New England Journal of MedicinePublished 16 January 2008
Erick H. Turner, Annette M. Matthews, Eftihia Linardatos, Robert A. Tell, Robert Rosenthal
Citations2,426
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A systematic literature search found that among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published, and the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.
Abstract
We cannot determine whether the bias observed resulted from a failure to submit manuscripts on the part of authors and sponsors, from decisions by journal editors and reviewers not to publish, or both. Selective reporting of clinical trial results may have adverse consequences for researchers, study participants, health care professionals, and patients.
Keywords
Decision SciencesMedicineEconomics, Econometrics and Finance
Computers Environment and Urban SystemsStatistical power analysis for the behavioral sciences
65,645 Citations1990
Controlled Clinical TrialsMeta-analysis in clinical trials
39,316 Citations1986Rebecca DerSimonian, Nan M. Laird
This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Journal of Educational StatisticsStatistical Methods for Meta-Analysis
10,479 Citations1988Stanley Wasserman, Larry V. Hedges +1 more
New England Journal of MedicineEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
4,666 Citations2007Steven E. Nissen, Kathy Wolski
Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
Journal of the Royal Statistical Society Series D (The Statistician)Meta-Analytic Procedures for Social Research.
4,283 Citations1994Andrew Metcalfe, R. Rosenthal
Journal of Clinical EpidemiologyPublication and related bias in meta-analysis
2,207 Citations2000Jonathan A C Sterne, David J. Gavaghan +1 more
Tests for small-study effects should routinely be performed in meta-analysis, particularly for moderate amounts of bias or meta-analyses based on a small number of small studies.
Personality and Social Psychology ReviewHARKing: Hypothesizing After the Results are Known
2,058 Citations1998Norbert L. Kerr
It is conceded that the question of whether HARKing's costs exceed its benefits is a complex one that ought to be addressed through research, open discussion, and debate.
JAMAEmpirical Evidence for Selective Reporting of Outcomes in Randomized Trials
1,806 Citations2004An‐Wen Chan, Asbjørn Hróbjartsson +3 more
The reporting of trial outcomes is not only frequently incomplete but also biased and inconsistent with protocols and Published articles, as well as reviews that incorporate them, may therefore be unreliable and overestimate the benefits of an intervention.
BMJThe case of the misleading funnel plot
1,758 Citations2006Joseph Lau, John P. A. Ioannidis +3 more
Evidence based medicine insists on rigorous standards to appraise clinical interventions, and failure to apply the same rules to its own tools could be equally damaging.
The LancetSelective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data
1,062 Citations2004Craig Whittington, Timothy J. Kendall +4 more
A meta-analysis of data from randomised controlled trials that evaluated an SSRI versus placebo in participants aged 5-18 years and that were published in a peer-reviewed journal or were unpublished and included in a review by the Committee on Safety of Medicines indicated that risks could outweigh benefits of these drugs to treat depression in children and young people.
Canadian Medical Association JournalThe appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey
1,041 Citations2007John P. A. Ioannidis, Thomas A Trikalinos
Annals of Internal MedicinePlacebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues
881 Citations2000Robert Temple, Susan S. Ellenberg
It is concluded that placebo-controlled trials may be ethically conducted even when effective therapy exists, as long as patients will not be harmed by participation and are fully informed about their alternatives.
BMJPublication bias: evidence of delayed publication in a cohort study of clinical research projects
829 Citations1997Jerome M Stern, R. J. Simes
Controlled Clinical TrialsPublication bias and clinical trials
721 Citations1987Kay Dickersin, Simon Chan +3 more
It appears that nonpublication was primarily a result of failure to write up and submit the trial results rather than rejection of submitted manuscripts, implying the existence of a publication bias of importance both to meta-analysis and the interpretation of statistically significant positive trials.
JAMAShort-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure
688 Citations2005Jonathan Sackner‐Bernstein, Marcin Kowalski +2 more
Compared with noninotrope-based control therapy, nesiritide may be associated with an increased risk of death after treatment for acutely decompensated heart failure and should be investigated in a large-scale, adequately powered, controlled trial.
BMJEvidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
639 Citations2003Hans Melander, Jane Ahlqvist-Rastad +2 more
Any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.
JAMAEffect of the Statistical Significance of Results on the Time to Completion and Publication of Randomized Efficacy Trials
629 Citations1998John P. A. Ioannidis
There is a time lag in the publication of negative findings that occurs mostly after the completion of the trial follow-up among randomized efficacy trials.
BMJIdentifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors
611 Citations2005An‐Wen Chan, Douglas G. Altman
Incomplete reporting of outcomes within published articles of randomised trials is common and is associated with statistical non-significance, the medical literature represents a selective and biased subset of study outcomes, and trial protocols should be made publicly available.
New England Journal of MedicineFailing the Public Health — Rofecoxib, Merck, and the FDA
589 Citations2004Eric J. Topol
On September 30, 2004, after more than 80 million patients had taken rofecoxib and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes.
JAMAEffect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
552 Citations2005Steven E. Nissen
Compared with placebo or pioglitazone, muraglitazar was associated with an excess incidence of the composite end point of death, major adverse cardiovascular events (MI, stroke, TIA), and CHF, which should not be approved to treat diabetes based on laboratory end points until safety is documented in a dedicated cardiovascular events trial.
JAMADepression Screening and Patient Outcomes in Cardiovascular Care
476 Citations2008Brett D. Thombs, Peter de Jonge +10 more
Depression treatment with medication or cognitive behavioral therapy in patients with cardiovascular disease is associated with modest improvement in depressive symptoms but no improvement in cardiac outcomes.
Canadian Medical Association JournalOutcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
446 Citations2004A.-W. Chan
Whether outcome reporting bias would be present in a cohort of government-funded trials subjected to rigorous peer review and whether primary outcomes specified in trial protocols were compared with those reported in publications is compared.
Journal of EpidemiologySystematic Evaluation and Comparison of Statistical Tests for Publication Bias
346 Citations2005Yasuaki Hayashino, Yoshinori Noguchi +1 more
Egger's linear regression method and Begg’s method had stronger statistical and discriminatory powers than Macaskill's method for detecting publication bias given the same type I error level.
PharmacoEconomicsPharmacoeconomic Evaluation in the Real World
245 Citations1999Dennis A. Revicki, Lori Frank
This brief review compares the 2 study designs as they relate to pharmacoeconomic evaluations in terms of the research questions they address, design differences and their implications for study bias, data collection and data analysis and the generalisability of their results.
JNCI Journal of the National Cancer InstituteSelective Reporting Biases in Cancer Prognostic Factor Studies
230 Citations2005P. Kyzas, Konstantinos T. Loizou +1 more
Selective reporting may spuriously inflate the importance of postulated prognostic factors for various malignancies and meta-analyses thereof should maximize retrieval of information and standardize definitions.
Statistics in MedicineConfronting publication bias: A cohort design for meta‐analysis
219 Citations1987R. J. Simes
A model is developed for pooling the results of clinical trials which is free from publication bias and is illustrated using the International Cancer Research Data Bank (ICRDB) registry of cancer clinical trials to evaluate the effect of chemotherapy on survival in advanced ovarian cancer.
The Medical Journal of AustraliaEvidence‐based medicine: useful tools for decision making
109 Citations2001Jonathan C. Craig, Les Irwig +1 more
The future holds promise for improved primary research, better EBM summaries, greater access to these summary, and better implementation systems for evidence‐based practice.
Critical CareStatistics review 5: Comparison of means.
64 Citations2002Elise Whitley, Jonathan Ball
The present review introduces the commonly used t-test, used to compare a single mean with a hypothesized value, two means arising from paired data, or two Means arising from unpaired data.
Evaluation & the Health ProfessionsIs There a “Best” Way to Detect and Minimize Publication Bias?
58 Citations2001Ba’ Pham, Robert W. Platt +3 more
It is shown that there are differences in the conclusions one would reach clinically based on the different analytical approaches dealing with publication bias, and the appropriate use of these methods improves the reliability and accuracy of meta-analysis.
PLoS MedicineA Taxpayer-Funded Clinical Trials Registry and Results Database
55 Citations2004Erick H. Turner
BMJAll members of primary care team are aware of importance of evidence based medicine
20 Citations1998Nicola A. Hagdrup, M Falshaw +2 more
Findings about the attitudes towards evidence based medicine of general practitioners in Wessex are presented, but they lack information from other members of the primary care team.